Back to top

Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with a price target of $31, up from $20. Published first on TheFl...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viridian Therapeutics, Inc. (VRDN)